Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics IncfiledCriticalAmicus Therapeutics Inc
Publication of AR111971A1publicationCriticalpatent/AR111971A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Se proveen métodos para el tratamiento de la enfermedad de Fabry en un paciente que tiene insuficiencia renal y/o proteinuria elevada. Ciertos métodos comprenden administrar al paciente entre aproximadamente 100 y aproximadamente 150 mg de equivalente de base libre de migalastat o una sal del mismo, a una frecuencia de una vez, día por medio. Ciertos métodos también proveen la estabilización de la función renal, reduciendo el índice de masa ventricular izquierda, reduciendo la globotriaosilsfingosina en plasma y/o incrementando la actividad de la a-galactosidasa A en el paciente.Methods are provided for the treatment of Fabry disease in a patient who has renal failure and / or elevated proteinuria. Certain methods comprise administering to the patient between about 100 and about 150 mg of migalastat free base equivalent or a salt thereof, at a frequency of once every other day. Certain methods also provide stabilization of renal function, reducing the left ventricular mass index, reducing plasma globotriaosylsphingosine and / or increasing the activity of α-galactosidase A in the patient.
ARP180101424A2017-05-302018-05-30
METHODS FOR TREATING PATIENTS WITH FABRY'S DISEASE WHO HAVE KIDNEY FAILURE
AR111971A1
(en)
Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy.